Low-strength tacrolimus eases atopic dermatitis

Article

Washington - Results from two multicenter, randomized, double-blind trials demonstrate that tacrolimus ointment 0.03 percent (Protopic) is a safe and effective treatment for mild to moderate atopic dermatitis in pediatric patients and adults.

Related Videos
Related Content

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Practical Back-to-School Tips: Educating Patients and Their Caregivers on Skin Health

August 15th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

August 1st 2023

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Practical Back-to-School Tips: Educating Patients and Their Caregivers on Skin Health

August 15th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

August 1st 2023

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Practical Back-to-School Tips: Educating Patients and Their Caregivers on Skin Health

August 15th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

August 1st 2023

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023
© 2023 MJH Life Sciences

All rights reserved.